Generate cancer model |
HSPCs; healthy human organoids |
Targeting the model type-related suppressors oncogenes |
Pooled lentivirus |
Disrupt suppressors or edit oncogenes |
Rapid, efficient, and inexpensive |
Special delivery techniques; tissue limited |
Synergistic gene study |
Cells |
Targeting optional drug target from database |
Lenti-double sgRNA library |
Together with deep sequencing |
Effective, low cost, innovative approach |
Double sgRNA construction; need highly efficient sgRNA; special analysis |
Target validation |
Drug or anticancer reagent resistant cells |
Lentiviral library from Addgene; or optional targets |
Plasmid |
Identify the target from resistant cells by sequencing |
Effective |
False-positives |
Gene diagnose |
Genome |
Target sensitive genes |
Lentivirus |
Together with Cas13a or Cas12a to induce collateral effects |
Sensitive, rapid, low cost |
Certain template concentration |